Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.53 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 4/20 | 0.41 |
| ▸ | CTSB | P07858 | 4/20 | 0.41 |
| ▸ | DPP4 | P27487 | 4/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.40 |
| ▸ | CTSH | P09668 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775289 | 1.00 | CTSK (0.53) | CTSKSLC15A1CTSLCTSBDPP4 | |
| SCHEMBL3326212 | 1.00 | CTSK (0.53) | CTSKSLC15A1CTSLCTSBDPP4 | |
| SCHEMBL4775282 | 1.00 | CTSK (0.53) | CTSKSLC15A1CTSLCTSBDPP4 | |
| SCHEMBL6031204 | 0.93 | CTSK (0.59) | CTSKSLC15A1CTSLCTSBDPP4 | |
| SCHEMBL8003112 | 0.93 | CTSK (0.59) | CTSKSLC15A1CTSLCTSBDPP4 | |
| SCHEMBL9572289 | 0.93 | CTSK (0.59) | CTSKSLC15A1CTSLCTSBDPP4 | |
| SCHEMBL4226584 | 0.92 | CTSK (0.43) | CTSKSLC15A1CTSLCTSBDPP4 | |
| SCHEMBL4226580 | 0.92 | CTSK (0.43) | CTSKSLC15A1CTSLCTSBDPP4 | |
| SCHEMBL1783728 | 0.86 | CTSK (0.56) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL14876797 | 0.86 | CTSK (0.56) | CTSKCTSLCTSBCTSHCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024018245-A1 | USE OF CALPAIN INHIBITORS FOR THE TREATMENT OF THE DIABETIC KIDNEY DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2024-01-25 | — | — | WO | disclosed |
| EP-3801581-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE CONTRACTURES | Children's Hospital Medical Center (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-2934573-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF AGING-RELATED LESIONS | Assistance Publique-Hôpitaux de Paris (FR) | 2015-10-28 | — | — | EP | disclosed |
| WO-2015032841-A2 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OR TREATMENT OF TH17 MEDIATED DISEASE | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-03-12 | — | — | WO | disclosed |
| WO-2014096087-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTION OF AGING-RELATED LESIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2014-06-26 | — | — | WO | disclosed |
| US-20100129343-A1 | Use Of A Compound For Enhancing The Expression Of Membrane Proteins On The Cell Surface | AXENTIS PHARMA AG (CH) | 2010-05-27 | — | — | US | disclosed |
| EP-2073849-A2 | METHODS AND COMPOSITIONS FOR GENE THERAPY | CANJI, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080220416-A1 | Compositions for Inhibiting Cell Growth and Inducing Apoptosis in Cancer Cells and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOI (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008060356-A2 | METHODS AND COMPOSITIONS FOR GENE THERAPY | CANJI, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20070218043-A1 | Use of a compound for enhancing the expression of membrane proteins on the cell surface | BIODEVELOPS PHARMA ENTWICKLUNG GMBH | 2007-09-20 | — | — | US | disclosed |
| EP-1771194-A2 | USE OF A DEUBIQUITINATING COMPOUND FOR ENHANCING THE EXPRESSION OF MEMBRANE PROTEINS ON THE CELL SURFACE | Biodevelops Pharma Entwicklung GmbH (AT) | 2007-04-11 | — | — | EP | disclosed |
| EP-1704250-A2 | METHODS FOR PREDICTING AND OVERCOMING RESISTANCE TO CHEMOTHERAPY IN OVARIAN CANCER AND FOR PREDICTING COLON CANCER OCCURRENCE | THE PENN STATE RESEARCH FOUNDATION (US) | 2006-09-27 | — | — | EP | disclosed |
| WO-2006002453-A2 | USE OF A DEUBIQUITINATING COMPOUND FOR ENHANCING THE EXPRESSION OF MEMBRANE PROTEINS ON THE CELL SURFACE | BIODEVELOPS PHARMA ENTWICKLUNG GMBH (AT) | 2006-01-12 | — | — | WO | disclosed |
| US-20060008454-A1 | Use of a compound for enhancing the expression of membrane proteins on the cell surface | DR. HELMUT BRUNAR | 2006-01-12 | — | — | US | disclosed |
| WO-2006001956-A2 | COMPOSITIONS FOR INHIBITING CELL GROWTH AND INDUCING APOPTOSIS IN CANCER CELLS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005066371-A2 | METHODS FOR PREDICTING AND OVERCOMING RESISTANCE TO CHEMOTHERAPY IN OVARIAN CANCER AND FOR PREDICTING COLON CANCER OCCURRENCE | THE PENN STATE RESEARCH FOUNDATION (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2000029573-A2 | ADENOVIRAL VECTORS | CANJI, INC. (US) | 2000-05-25 | — | — | WO | disclosed |
| EP-0995757-A2 | Bivalent inhibitors of the proteasome | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2000-04-26 | — | — | EP | disclosed |
| WO-1997032605-A1 | CYTOMEGALOVIRUS NUCLEIC ACIDS ENCODING PROTEINS HAVING NORMAL OR ALTERED CLASS I MHC BINDING AND TREATMENT OF DISEASES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1997-09-12 | — | — | WO | disclosed |